Time to Revisit Using 10-Year Risk to Guide Statin Therapy

JAMA Cardiol. 2022 Aug 1;7(8):785-786. doi: 10.1001/jamacardio.2022.1883.

Authors

Ann Marie Navar^{1

2}, Gregg C Fonarow^{3

4}, Michael J Pencina^{5

6}

Affiliations

¹ Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
² Deputy Editor, Diversity, Equity, and Inclusion, JAMA Cardiology.
³ Department of Medicine, University of California, Los Angeles.
⁴ Associate Editor for Health Care Quality an Guidelines, JAMA Cardiology.
⁵ Department of Biostatistics, Duke University Medical Center, Durham, North Carolina.
⁶ Deputy Editor for Statistics, JAMA Cardiology.

PMID: 35793080
DOI: 10.1001/jamacardio.2022.1883

No abstract available

MeSH terms

Cardiovascular Diseases* / drug therapy
Cardiovascular Diseases* / prevention & control
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Primary Prevention

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors